

# Phylos Secures Strategic Investment from Organigram to Accelerate Cannabis Genetics Platform

*Investment strengthens development of scientifically bred, F1 hybrid cannabis genetics for growers across markets*

PORTLAND, OR, UNITED STATES, December 31, 2025 /EINPresswire.com/ -- Phylos, a cannabis genetics company focused on modern plant breeding, today announced the closing of a strategic investment led by Organigram Holdings Inc. (NASDAQ: OGI, TSX: OGI), a leading licensed producer and publicly traded cannabis company. The investment deepens the long-standing collaboration between the two companies and supports continued development of Phylos' cannabis genetics platform.

Organigram, one of the world's largest indoor cannabis producers, was an early adopter of F1 hybrid seed-based cannabis production, recognizing that scientifically bred genetics are foundational to consistency, scale, and quality. Through this investment, Organigram gains priority access to selected genetics, while Phylos continues to advance its broader breeding and development roadmap.

"Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics," said Ralph Risch, CEO of Phylos. "Their investment allows us to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale."

Phylos' genetics platform is designed to improve outcomes for all growers by combining uniform, reliable performance within cultivars with a broad and continuously evolving portfolio of genetically and phenotypically distinct hybrids. The company's breeding program integrates large-scale field data, modern breeding techniques, and rapid iteration to deliver improvements in yield, predictability, disease resistance, and production efficiency.

The expanded partnership reflects a shared long-term view that cannabis production is moving toward modern agricultural systems built on predictable, data-driven genetics.

For more information, visit [www.phylos.bio](http://www.phylos.bio).

Madelyn Bechtel

Phylos Bioscience  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/879576629>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.